P16 Staining as Prognostic Biomarker in Serous Papillary Endometrial Cancer
Completed
- Conditions
- Serous Papillary Endometrial Cancer
- Interventions
- Other: no intervention
- Registration Number
- NCT01267357
- Lead Sponsor
- Rambam Health Care Campus
- Brief Summary
P16 is a tumor suppressor protein implicated in serous papillary endometrial carcinoma. Evidence from previous trials indicates that it may be used as a diagnostic biomarker distinguishing this disease from endometrioid endometrial cancer. Additional evidence points to its prognostic value.
The current study will evaluate p16 both as a diagnostic tool for serous papillary endometrial cancer and as a prognostic biomarker.
following anonymization, histology blocks will be microtomed and stained for P16 and P53 proteins.
Blocks from endometrioid endometrial cancer will be used as a control group.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 62
Inclusion Criteria
- diagnosis of endometrial cancer
- histology block exists in hospital's library
Exclusion Criteria
- none
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Serous papillary endometrial ca patients no intervention 30 patients diagnosed with SP endometrial ca Endometrioid endometrial ca no intervention 32 patients diagnosed with Endometrioid endometrial ca
- Primary Outcome Measures
Name Time Method Overall survival last followup (2-10 years)
- Secondary Outcome Measures
Name Time Method progression free survival Current follow up (2-10 years) correlation of P16 stain with histological diagnosis at last follow up (2-10 years)
Trial Locations
- Locations (1)
Rambam Medical Center
🇮🇱Haifa, Israel